AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study - Zacks.com

AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study  Zacks.com

AstraZeneca (AZN) announces positive overall survival results from the phase III CASPIAN study evaluating Imfinzi in first-line extensive-stage SCLC.



Comments

Popular posts from this blog

Oncology: The disease, dynamics & challenges of market research

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Lung Cancer Among People Who Never Smoked